Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice.
Gema AricetaFernando SantosAndrés López MuñizAlvaro HermidaMaria Luisa MatosesAna VenturaPaloma Leticia Martin-MorenoEsther GonzálezLaura AcuñaElisa GinerJulia VaraPublished in: Clinical kidney journal (2024)
Switching from IR to ER cysteamine in clinical practice reduces hospital stays, improves nutritional status and growth in paediatric patients and could help to enhance treatment tolerability by reducing side effects. Furthermore, the dosing of ER cysteamine could promote therapeutic compliance and positively affect the quality of life of the NC population.
Keyphrases
- clinical practice
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- emergency department
- healthcare
- estrogen receptor
- intensive care unit
- peritoneal dialysis
- endoplasmic reticulum
- open label
- breast cancer cells
- randomized controlled trial
- patient reported outcomes
- combination therapy
- phase ii
- smoking cessation